This clinical trial is focused on studying the treatment of patients experiencing a severe heart condition known as myocardial infarction, commonly referred to as a heart attack, which has led to a serious complication called cardiogenic shock or cardiac arrest. These patients require a special type of life support called VA-ECMO (Veno-Arterial Extracorporeal Membrane Oxygenation), which helps their heart and lungs function. The study is testing a treatment that combines two medications: cangrelor and bivalirudin. Cangrelor is given as an injection or infusion and is used to prevent blood clots, while bivalirudin is another medication that helps prevent clotting during medical procedures.

The purpose of this study is to evaluate how well this combination of medications works in preventing blood clots and reducing the risk of bleeding in patients undergoing a procedure called PCI (Percutaneous Coronary Intervention), which is often used to treat heart attacks. The study will monitor patients to see if the treatment effectively prevents clotting issues and minimizes bleeding problems. Patients will receive cangrelor and bivalirudin, with the doses adjusted based on specific tests that measure how well the blood is clotting.

Throughout the study, the focus will be on ensuring the safety and effectiveness of the treatment. The study will track any occurrences of blood clots or bleeding events while patients are receiving cangrelor. The goal is to find a balance where the treatment is effective in preventing clots without causing significant bleeding. This research aims to improve the care and outcomes for patients with severe heart conditions requiring advanced support like VA-ECMO.